Thromboembolism in COVID-19 Laboratory Considerations
Michael P Gulseth, PharmD, BCPS, FMSHP, FASHP
Program Director for Anticoagulation Services, Sanford USD Medical Center & Clinical,Associate Professor, Dept of Internal Medicine, University of South Dakota Sanford School of Medicine
o provide a discussion of the thromboembolism risk of COVID-19 and how risk factors relate to laboratory medicine results, the presentation will include case based discussions on how different laboratory values can aid in identifying those at risk of thromboembolic complications. Further, for patients requiring therapeutic heparin infusions for active thromboembolism treatment, optimal monitoring strategies will be covered, along with the possible need for post discharge prophylaxis.
- Describe what is currently known about the etiology and proposed pathophysiology of thromboembolism in COVID-19
- Identify laboratory parameters that may help identify patients at risk of thromboembolic complications in COVID-19
- When presented with a COVID-19 case, choose an appropriate thromboembolic prevention strategy
- When presented with a COVID-19 case with a likely or confirmed thromboembolism, choose an appropriate thromboembolic treatment strategy